evipedia.ai
← Back

GLA for Health & Longevity

Evidence Review created on 09/19/2026 using AI4L / Opus 5

Also known as: Gamma-Linolenic Acid, Gamolenic Acid, γ-Linolenic Acid, 18:3n-6

Motivation

GLA (gamma-linolenic acid) is an unusual member of the omega-6 fat family. It occurs in quantity in only a few seed oils — evening primrose, borage and black currant — and, unlike the omega-6 fats that dominate modern diets, it is converted in the body into a fat that feeds signals which damp inflammation rather than drive it. That is why a fat from the family usually blamed for inflammation has been sold for four decades as an anti-inflammatory.

The body makes small amounts of GLA from the ordinary omega-6 fat in vegetable oils, but the enzyme that performs it works less well with advancing age, poor blood sugar control and heavy alcohol intake. That is the argument for supplying GLA ready-made. Seed-oil capsules were licensed as medicines in several countries during the 1980s, then withdrawn when larger trials failed to confirm the early skin results, while trials in other conditions kept reporting benefit.

This review examines what controlled human evidence shows about GLA taken as a supplement: where an effect holds and where it does not, what happens to the body’s fat balance when GLA is taken without omega-3, and what is known about dose, sourcing and monitoring.

Benefits - Risks - Protocol - Conclusion

High-level overviews of GLA that discuss the compound or its immediate metabolic pathway in substantial depth.

Content from five of the six priority platforms could not be included: Found My Fitness, Peter Attia, Andrew Huberman, Chris Kresser and Lifespan.io have published no article, episode or commentary that treats GLA in substantial depth, because their omega-6 coverage addresses linoleic acid intake and the omega-6 to omega-3 ratio rather than this specific fat.

Grokipedia

  • Linolenic acid

    Grokipedia has no standalone GLA entry; this is its primary article covering the compound, which it treats as one of the two linolenic acid isomers with its own chemistry and metabolism subsections.

Examine

  • Evening Primrose Oil

    Examine has no standalone GLA page; this intervention monograph is its primary coverage, grading the evidence for the main GLA-bearing oil by condition and setting out the bleeding and seizure safety debate.

ConsumerLab

Systematic Reviews

A real-time PubMed search for systematic reviews and meta-analyses of GLA and the GLA-bearing seed oils returned the papers below, which cover the claimed effects and drug-comparative tolerability, but no systematic review or meta-analysis addresses GLA’s principal theoretical harm — accumulation of arachidonic acid during supplementation without omega-3 — so that side of the trade-off is unrepresented in this section.

Mechanism of Action

GLA is the first product of omega-6 fat processing in the body. Linoleic acid (LA, the main omega-6 fat in vegetable oils) is converted to GLA by delta-6 desaturase, the enzyme encoded by the FADS2 gene that inserts a double bond and sets the pace of the whole pathway. Supplying GLA directly bypasses that rate-limiting step.

Almost no GLA accumulates in tissue. It is lengthened within hours by ELOVL5, a fatty-acid chain-lengthening enzyme, into dihomo-gamma-linolenic acid (DGLA), which is stored in cell membranes. DGLA is the active species. Cyclooxygenase (COX, the enzyme aspirin blocks) converts DGLA into prostaglandin E1 (PGE1, a signalling lipid that widens blood vessels and calms immune cells), and 15-lipoxygenase (15-LOX, an enzyme that adds oxygen to fats) converts it into 15-HETrE, which blocks assembly of leukotrienes, the lipids that recruit inflammatory cells.

The competing account is unfavourable. Delta-5 desaturase, encoded by FADS1, carries DGLA onward to arachidonic acid (AA), the raw material for the inflammation-driving prostaglandins and leukotrienes. Whether supplemental GLA is on balance calming or inflaming depends on how much of it stops at DGLA. Eicosapentaenoic acid (EPA, a long-chain omega-3 from fish oil) inhibits delta-5 desaturase and holds the pathway at DGLA.

GLA has no receptor and no selectivity in the pharmacological sense; it acts as a substrate. Plasma GLA clears within hours through elongation and beta-oxidation (burning fat for energy); membrane DGLA enrichment plateaus at roughly three weeks and washes out over about four weeks.

Historical Context & Evolution

Evening primrose (Oenothera biennis) was used by Native American peoples as food and as a dressing for skin complaints and bruising; European settlers carried the plant home in the seventeenth century, where its oil became a folk remedy. GLA itself was identified in evening primrose seed oil in 1919 and named for the position of its first double bond.

Interest turned clinical in the 1970s and 1980s through David Horrobin, who argued that delta-6 desaturase activity falls with age, diabetes, alcohol intake and zinc deficiency, and that supplying GLA would restore the downstream signalling lipids. His companies, Efamol and Scotia Pharmaceuticals, funded most of the early trials. Two evening primrose oil products were licensed as medicines in the United Kingdom — Epogam for atopic dermatitis (a chronic itchy inflammatory skin disease) in 1988, and Efamast for cyclical breast pain.

Those licences were withdrawn in October 2002 after the UK regulator judged the accumulated trial evidence insufficient to support the eczema claim. What changed was not one refutation but the arrival of larger, independently funded trials with smaller or null results, culminating in a 2013 pooled analysis of 27 studies that found no eczema benefit. Evidence moved the other way too: controlled trials in diabetic nerve damage and in rheumatoid arthritis reported benefit, and the nerve-damage signal was reproduced in a 2024 pooled analysis. The standing of GLA therefore now differs sharply by indication rather than resolving in one direction.

Expected Benefits

High 🟩 🟩 🟩

Relief of Painful Diabetic Peripheral Neuropathy

Diabetic peripheral neuropathy is nerve damage in the feet and hands caused by long-standing high blood sugar, producing burning pain, numbness and slowed nerve signals. GLA is thought to restore the nerve blood supply that impaired delta-6 desaturase degrades. The evidence is a randomised controlled trial (a study allocating participants to treatment or placebo by chance) of 111 patients over a year, a smaller second trial, a comparison against alpha-lipoic acid, and a 2024 network meta-analysis of 11 trials. Most participants had mild disease.

Magnitude: In the 2024 network meta-analysis, GLA lowered the Total Symptom Score (a validated four-item neuropathy symptom scale) by a standardised mean difference (the effect expressed in units of the outcome’s own spread) of −2.39 versus placebo (95% confidence interval, the range within which the true value most likely lies, −4.3 to −0.5). In the multicentre trial at 480 mg/day, all 16 nerve measurements favoured GLA over one year, 13 of them significantly.

Reduction of Rheumatoid Arthritis Joint Pain and Tenderness

Rheumatoid arthritis is an autoimmune disease in which the immune system attacks joint linings, causing swelling, pain and morning stiffness. The proposed mechanism is displacement of arachidonic acid by DGLA in the white blood cells that infiltrate the joint. Two placebo-controlled trials support it, at 1.4 and 2.8 g/day for six to twelve months, and a Cochrane review judged GLA one of the few herbal therapies with consistent evidence. Both trials were small, and benefit needed doses far above supplement labels.

Magnitude: In the 1996 randomised trial at 2.8 g/day, a meaningful response — at least 25% improvement on four disease measures — was reached by 14 of 22 patients on GLA versus 4 of 19 on placebo at six months. The 1993 trial at 1.4 g/day reported reduced joint tenderness and swelling over 24 weeks.

Medium 🟩 🟩

Improvement in Dry Eye Symptoms

Dry eye, or keratoconjunctivitis sicca, is a chronic failure of the tear film that produces grittiness, burning and blurred vision, and becomes common after the menopause. GLA is proposed to reduce inflammatory activation of the immune cells lining the eye surface. Two small randomised trials support it, one in 38 post-menopausal women, one in 26 patients. Both paired GLA with other fatty acids, so the effect cannot be attributed to GLA alone.

Magnitude: In the six-month randomised trial, the Ocular Surface Disease Index (a validated 12-item symptom questionnaire) fell to 21 ± 4 on GLA plus omega-3 versus 34 ± 5 on placebo at 24 weeks. Tear production and corneal staining did not change. The earlier trial reported reduced ocular surface inflammation on linoleic acid plus GLA.

Maintenance of Bone Mineral Density in Older Adults

Bone mineral density is the standard measure of bone strength and the accepted predictor of fracture; it falls steadily after mid-life. GLA is proposed to raise calcium absorption and its deposition into bone through prostaglandin E1. One randomised trial in 65 women of mean age 79, all on supplemental calcium, supports it over 18 months, with an open extension to 36 months. It has never been replicated, and the supplement combined GLA with EPA, so the contribution of GLA alone is unresolved.

Magnitude: In that trial, lumbar spine density held steady on GLA plus EPA plus calcium while falling 3.2% on calcium plus placebo; thigh bone density rose 1.3% versus a 2.1% fall. Over the second 18 months, spine density rose 3.1% in those who stayed on treatment.

Reduction of Acne Lesions

Acne vulgaris is inflammation of the skin’s oil glands producing spots and cysts. GLA is proposed to lower interleukin-8, a protein that summons inflammatory cells into the follicle. One randomised, double-blind, controlled trial in 45 adults with mild to moderate acne supports it over ten weeks, with skin biopsies confirming reduced inflammation. It has not been replicated, the dose was low, and an omega-3 arm performed similarly, so the effect is not specific to GLA.

Magnitude: In the ten-week randomised trial, borage oil supplying 400 mg/day of GLA significantly reduced both inflammatory and non-inflammatory lesion counts against an untreated control, alongside falls in interleukin-8 staining intensity on biopsy; the report plots the lesion counts over time and gives no outcome figure.

Reduction of Raynaud’s Phenomenon Attacks

Raynaud’s phenomenon is an exaggerated narrowing of the small arteries of the fingers and toes on cold exposure, producing blanching, numbness and pain. GLA is proposed to raise prostaglandin E1, which widens blood vessels and inhibits platelet clumping. One double-blind controlled trial in 21 patients, 11 of them given evening primrose oil for eight weeks and 10 placebo, supports it. The benefit was symptomatic only: hand temperature and blood-flow measurements did not move, and the trial has never been repeated.

Magnitude: In the 1985 double-blind trial, attacks became significantly more frequent in the placebo group than on evening primrose oil as the weather cooled, and severity and hand-coldness scores improved only on treatment; the report gives no attack-rate figure, and cold-challenge blood-flow measurements were unchanged.

Low 🟩

Improvement in Blood Fats ⚠️ Conflicted

Individual trials reported triglyceride falls and HDL cholesterol rises, but the pooled primary analysis of six randomised trials found no effect on any blood fat. The positive findings survive only in subgroups defined after the fact. The net reading is that GLA does not reliably alter blood fats.

Magnitude: In the 2020 meta-analysis, triglycerides fell 37.28 mg/dL (95% confidence interval −73.53 to −1.03) at doses of 4 g/day or less, and HDL cholesterol rose 5.47 mg/dL (95% confidence interval 1.32 to 9.61) in participants with raised blood fats — both subgroup results only.

Relief of Atopic Dermatitis Symptoms ⚠️ Conflicted

Early small trials and a manufacturer-sponsored pooled analysis reported reduced itch and redness, with blood GLA levels tracking the response. Larger independently funded trials did not reproduce it, and a company trial of the downstream compound stopped early. The net reading is that oral GLA does not improve eczema.

Magnitude: In the 2013 Cochrane review, participant-rated global eczema symptoms differed by −2.22 points on a 0–100 scale (95% confidence interval −10.48 to 6.04) across seven trials — a confidence interval narrow enough to exclude any useful benefit.

Improvement in Skin Barrier Function with Age

Ageing skin loses water faster because it can no longer make GLA locally. Borage oil in 29 adults of mean age 69 cut water loss through the skin and abolished reported itch, alongside the expected membrane DGLA rise. Being uncontrolled, the symptom findings carry a large placebo component.

Magnitude: In that study, water loss through the skin fell 10.8% over two months on 360–720 mg/day of GLA, with reported itch falling from 34% of participants to none and dry skin from 42% to 14%.

Relief of Cyclical Breast Pain ⚠️ Conflicted

Early trials in cyclical breast pain were strong enough to license a GLA medicine in the United Kingdom, but pooled analysis of thirteen trials found no advantage over placebo or active comparators. The net reading is that GLA does not relieve cyclical breast pain.

Magnitude: In the 2021 meta-analysis, evening primrose oil moved breast pain severity by a standardised mean difference of −0.37 (95% confidence interval −0.76 to 0.03) against placebo across five trials and 525 patients, and did not outperform danazol, topical anti-inflammatories or vitamin E across the full thirteen trials and 1,752 patients.

Relief of Menopausal Hot Flushes ⚠️ Conflicted

Hot flushes are sudden waves of heat and sweating after the menopausal fall in oestrogen. A six-month randomised trial of evening primrose oil found no advantage over placebo; a 2024 systematic review found lower severity but unchanged frequency. The net reading is that GLA does not reliably relieve hot flushes.

Magnitude: In the 1994 randomised trial of 56 women, daytime flushes fell by 1.9 per day on placebo against 0.5 on GLA. A 2024 systematic review found lower severity only with courses under six months, and no change in frequency or duration.

Relief of Asthma Symptoms ⚠️ Conflicted

A GLA plus EPA emulsion improved asthma-related quality of life and cut rescue inhaler use in two randomised adult trials run by its maker; only one beat placebo, and two 1980s evening primrose oil trials found nothing. The net reading is that oral GLA does not reliably relieve asthma.

Magnitude: In the 2009 randomised trial, the Mini Asthma Quality of Life Questionnaire (a validated 15-item score) rose 0.73 points on the GLA plus EPA emulsion against a 0.22 fall on placebo over 28 days, while asthma control scores did not separate. The 2008 trial found the same emulsion no better than placebo for self-reported asthma status.

Speculative 🟨

Prevention of Weight Regain After Weight Loss

The basis is rodent work: raising membrane arachidonic acid improves fuel partitioning and blocks regain. A 302-participant randomised trial completed in 2023, but no outcome has been published, so no controlled human result exists.

Restoration of Age-Impaired Fatty-Acid Desaturation

The basis is mechanistic: delta-6 desaturase activity declines with age, and supplemental GLA demonstrably raises membrane DGLA and the DGLA-to-arachidonic-acid ratio. No trial has tested whether correcting that biochemistry changes any age-related health outcome.

Benefit-Modifying Factors

  • FADS1 and FADS2 genotype: Carriers of the minor alleles at the FADS gene cluster (for example rs174537, rs174547) desaturate omega-6 fats poorly and carry less GLA and DGLA. Because supplemental GLA bypasses the slow delta-6 step, these low converters have the most headroom to gain.

  • Baseline DGLA and arachidonic acid levels: A low starting DGLA level, or a low DGLA-to-arachidonic-acid ratio on a fatty-acid panel, predicts the largest membrane shift on supplementation. Those already high in DGLA have little room to move and should expect less.

  • Baseline omega-3 status: A low Omega-3 Index (the share of long-chain omega-3 fats in red blood cell membranes) means nothing restrains delta-5 desaturase, so more supplied GLA runs on to arachidonic acid and less of the intended effect is realised.

  • Sex: Oestrogen upregulates delta-6 desaturase, so pre-menopausal women convert linoleic acid to GLA more efficiently than men and gain proportionally less from bypassing that step. Most positive trials in breast pain and menopause enrolled women exclusively.

  • Pre-existing conditions: Diabetes, insulin resistance, heavy alcohol intake, and zinc or magnesium deficiency all suppress delta-6 desaturase. The diabetic neuropathy result is the clearest case of a condition that both impairs conversion and responds to replacement.

  • Age: Delta-6 desaturase activity declines across adult life, so older adults start further from adequate GLA. The skin-barrier and bone trials were both conducted in adults aged 69 and over, the end of the target range where effects should be largest.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Intolerance

Nausea, abdominal bloating, loose stools and belching are the most frequently recorded complaints in GLA and seed-oil trials, and the commonest reason for withdrawal. The mechanism is the oil load itself rather than GLA, since placebo oils produce them at similar rates. Evidence comes from pooled trial safety data across two large reviews. Effects are mild, transient and fully reversible on stopping, and are reduced by dividing the dose and taking capsules with food. No long-term gastrointestinal harm has been documented.

Magnitude: In the mastalgia meta-analysis, adverse events — nausea and abdominal bloating chief among them — occurred in 291 per 1,000 patients on evening primrose oil (95% confidence interval 213 to 402) against 327 per 1,000 on placebo, across two trials and 325 patients. The Cochrane eczema review of 27 trials found the same mild, transient, mainly gastrointestinal effects in active and placebo groups alike.

Headache and Dizziness

Headache and light-headedness are the second most reported complaints in seed-oil trials, appearing in both active and placebo arms. No mechanism has been established; the pattern is consistent with the non-specific symptom reporting seen in any oil-capsule trial. Evidence is pooled adverse-event data from a 13-trial meta-analysis, with supporting reports in the eczema literature. Symptoms are mild and resolve on discontinuation. They are worth distinguishing from gastrointestinal effects because they do not respond to taking capsules with food.

Magnitude: In the mastalgia meta-analysis, headache and giddiness sat inside a pooled adverse-event rate of 291 per 1,000 on evening primrose oil against 327 per 1,000 on placebo, and occurred no more often than on topical anti-inflammatories, danazol or vitamin E across 1,752 randomised patients.

Medium 🟥 🟥

No risk sits at Medium: nothing is established by a single controlled human trial or by consistent observational cohort data, since the hazards above rest on pooled adverse-event data from multiple trials and those below on uncontrolled case reports and on biomarker measurements never validated against health outcomes.

Low 🟥

Increased Bleeding on Anticoagulant or Antiplatelet Therapy

GLA yields prostaglandin E1, which inhibits platelet clumping, so an additive effect with anticoagulants is expected. The evidence is a report of increased bleeding on warfarin from the Cochrane safety search, plus surveys of herb-drug combinations in older adults. No trial has measured bleeding events.

Magnitude: Not quantified in available studies. No controlled trial has measured bleeding outcomes on GLA, and the Cochrane review’s safety search and the interaction survey identified only case-level reports, which cannot yield an event rate.

Lowered Seizure Threshold ⚠️ Conflicted

Two early 1980s reports in patients on phenothiazine antipsychotics generated a warning that persists in product labelling. A 2007 re-examination called it spurious, noting that GLA’s metabolites are anticonvulsant in animals. The net reading is that the warning rests on uncontrolled reports later analysis did not substantiate.

Magnitude: Not quantified in available studies. The 2007 re-examination found the original signal traceable to two case reports with no denominator, and no controlled trial has since measured seizure incidence on GLA.

Speculative 🟨

Rise in Circulating Arachidonic Acid without Omega-3

Feeding studies show serum arachidonic acid climbing on GLA alone and staying flat when EPA is added (1997, 2000). It is an unvalidated biomarker: levels showed no mortality link in older adults.

Suppression of T-Lymphocyte Proliferation

A randomised trial in adults aged 55–75 found 770 mg/day cut stimulated lymphocyte multiplication by up to 65%, partly reversing after stopping (2001). The assay has never been linked to infection or cancer risk.

Pyrrolizidine Alkaloid Exposure from Borage Products

Borage contains pyrrolizidine alkaloids, plant compounds toxic to the liver, and residues can carry into unrefined seed oil. No human outcome data exist for GLA products; the concern is extrapolated from other alkaloid-bearing herbs.

Risk-Modifying Factors

  • FADS1 genotype: Carriers of the high-activity delta-5 desaturase alleles convert DGLA onward to arachidonic acid faster, so they see the largest omega-6 shift on unopposed GLA and gain the most from pairing it with omega-3.

  • Baseline omega-3 status and arachidonic acid level: A low Omega-3 Index or an already high arachidonic acid level leaves delta-5 desaturase unrestrained, amplifying the membrane shift that is the principal theoretical harm of GLA taken alone.

  • Sex: Women supply the great majority of the recorded adverse-event data, because the breast pain and menopause trials were female-only. No sex-specific safety signal has emerged, and none of the reported effects differ by sex.

  • Pre-existing conditions: Bleeding disorders, anticoagulant or antiplatelet therapy, and imminent surgery raise the bleeding concern. Liver disease raises the alkaloid concern for borage-derived products specifically. A seizure history is the historical, and contested, caution.

  • Age: Older adults carry the risk not through altered handling of GLA but through polypharmacy: anticoagulant, antiplatelet and anti-inflammatory prescribing all rise with age, and each overlaps with the bleeding concern.

Key Interactions & Contraindications

  • Vitamin K antagonists: Warfarin, acenocoumarol, phenprocoumon. Caution; additive impairment of clotting, with one report of increased bleeding. The mitigating step is a repeat international normalised ratio (INR, a standardised clotting time) 1–2 weeks after starting GLA and after any dose change.

  • Direct oral anticoagulants: Apixaban, rivaroxaban, edoxaban, dabigatran. Caution; additive bleeding risk with no laboratory test to track it. No dose adjustment is established; the practical step is to avoid combining GLA with a second platelet-inhibiting supplement.

  • Antiplatelet agents: Aspirin, clopidogrel, prasugrel, ticagrelor, dipyridamole. Caution; prostaglandin E1 inhibits platelet clumping through a different route than these drugs, so effects add. Prompt reporting of new bruising, nosebleed or dark stool is the practical safeguard.

  • Phenothiazine antipsychotics: Chlorpromazine, fluphenazine, trifluoperazine. Historical caution for seizures, since shown to rest on two uncontrolled reports. No mitigating action is established beyond the usual seizure monitoring already in place for these drugs.

  • Over-the-counter medications: Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs, painkillers such as ibuprofen and naproxen that block prostaglandin formation). Caution; additive stomach irritation and bleeding risk. Mitigation is dosing GLA with food and separating it from the NSAID dose.

  • Fish oil and other omega-3 supplements: EPA and DHA (docosahexaenoic acid, the other long-chain omega-3). Potentiating and intended; EPA blocks delta-5 desaturase and prevents the arachidonic acid rise. Only the small additive bleeding effect warrants monitoring.

  • Platelet-inhibiting supplements: Ginkgo biloba, high-dose garlic, high-dose vitamin E (above 400 international units), nattokinase, curcumin. Caution; additive bleeding risk. Mitigation is separating them from GLA or limiting the total number taken concurrently.

  • Sesame lignans: Sesamin, sesamolin, often co-formulated with GLA. No caution required, and potentiating; they inhibit delta-5 desaturase and hold more of the supplied GLA at DGLA. No mitigating action needed; this is the reason for the pairing.

  • Surgical and dental procedures: Any intervention with bleeding risk, including colonoscopy with biopsy and epidural placement. Caution; additive bleeding. Standard practice is stopping GLA 10–14 days beforehand and restarting once clotting is confirmed.

Populations who should avoid GLA:

  • Inherited or acquired bleeding disorders — haemophilia, von Willebrand disease, or platelet count below 50 × 10⁹/L
  • Elective surgery scheduled within 14 days, or any unhealed surgical or procedural wound
  • Pregnancy, particularly from 37 weeks, where evening primrose oil is used to soften the cervix and hasten labour
  • Known allergy to the source plant — evening primrose, borage, black currant — or to the soy lecithin used in many capsule shells
  • Chronic liver disease at Child-Pugh Class B or C (a scoring system for liver failure severity) when the product is borage-derived, because of pyrrolizidine alkaloid exposure

Risk Mitigation Strategies

  • Pairing GLA with an EPA-containing omega-3: Roughly 1 g of combined EPA and DHA per 1 g of GLA. EPA blocks delta-5 desaturase, preventing the rise in arachidonic acid that is GLA’s principal theoretical harm.

  • Low start with slow titration: Protocols begin at 240–360 mg/day of GLA with food and rise by 240 mg every 1–2 weeks to the target. This limits the nausea, bloating and loose stools that drive most withdrawals.

  • Splitting the daily dose: Two or three divided doses taken with meals rather than one bolus. The gastrointestinal complaints track the oil load per dose, not the daily total.

  • Interruption before procedures: Discontinuation 10–14 days before elective surgery, dental extraction, colonoscopy with biopsy or epidural placement removes the additive platelet-inhibiting effect before any bleeding risk.

  • Repeat clotting test on warfarin: A further international normalised ratio 1–2 weeks after starting GLA and after each dose change catches the additive anticoagulant effect before bleeding occurs.

  • Alkaloid-free borage, or evening primrose instead: Certified pyrrolizidine-alkaloid-free borage oil, or evening primrose oil, which is not an alkaloid-bearing plant, removes the liver exposure concern entirely.

  • Fresh, cold-stored stock: Nitrogen-flushed, refrigerated product with a stated peroxide value and a distant expiry date, refrigerated after opening. Rancid polyunsaturated oil delivers the oxidised fats that drive the gastrointestinal complaints.

Therapeutic Protocol

  • Standard anti-inflammatory dose: 400–500 mg/day of GLA taken with an omega-3 supplement, the regimen Life Extension has promoted since the 1990s and the dose at which its sesame-lignan formulation is sold. Note that the same company sells the product.

  • Disease-level dose: 1.4–2.8 g/day of GLA, the range used in the rheumatoid arthritis trials run by Robert Zurier’s group at the University of Massachusetts. This requires 6–14 g of borage oil or far more evening primrose oil.

  • Neuropathy dose: 360–480 mg/day, the doses used in the Gamma-Linolenic Acid Multicenter Trial Group study and in Jamal’s earlier work, continued for at least six to twelve months before judging response.

  • Competing approach — whole oil versus concentrate: The botanical tradition favours whole borage or evening primrose oil for its accompanying linoleic acid; the pharmacological tradition favours purified GLA or GLA-safflower concentrates for dose precision. The two have never been compared.

  • Competing approach — GLA alone versus with omega-3: The original Efamol protocols used GLA unopposed. The Wake Forest group’s feeding work showed EPA blocks the arachidonic acid rise, and most practice now follows it. No trial has compared them clinically.

  • Best time of day: With the largest meal, and with the omega-3 dose if these are separate products. Meal fat improves absorption of the oil; no morning or evening advantage has been demonstrated.

  • Half-life: Plasma GLA is cleared within hours by elongation and fat burning. The meaningful timescale is the membrane one: DGLA enrichment plateaus at about three weeks and falls back over about four weeks after stopping.

  • Single versus split dosing: Split for any total above about 500 mg/day of GLA, because tolerability tracks the oil load per dose. Below that, once daily is adequate; membrane loading depends on the daily total, not the schedule.

  • Genetic considerations: Minor-allele carriers at FADS2 desaturate poorly and benefit most from bypassing the step. High-activity FADS1 carriers convert DGLA onward faster and have the strongest case for pairing GLA with EPA rather than taking it alone.

  • Sex-based differences: Oestrogen upregulates delta-6 desaturase, so pre-menopausal women make more of their own GLA and may need less. Post-menopausal women lose that advantage. No trial has set doses by sex.

  • Age-related considerations: Delta-6 desaturase activity falls across adult life, so adults at the older end of the range start further from adequate GLA. The skin and bone trials used 360–720 mg/day in adults aged 69 and over.

  • Baseline biomarkers: A fatty-acid panel showing low DGLA, a low DGLA-to-arachidonic-acid ratio and a low Omega-3 Index identifies the strongest candidates. High baseline arachidonic acid argues for loading omega-3 first, then adding GLA.

  • Pre-existing conditions: Diabetes, insulin resistance, heavy alcohol intake and zinc deficiency all suppress delta-6 desaturase and predict a larger response. Anticoagulant use, a bleeding disorder or imminent surgery override the dose choice entirely.

Discontinuation & Cycling

  • Lifelong or short-term: GLA behaves as ongoing replacement, not a course. Membrane DGLA returns toward baseline within roughly four weeks of stopping, and the trials that showed benefit maintained dosing continuously for six to eighteen months.

  • Withdrawal effects: None documented. The lymphocyte suppression seen in older adults reversed partially within four weeks of stopping, and no trial has reported a rebound in symptoms, inflammation or any measured biomarker after discontinuation.

  • Tapering: Not applicable. No physiological adaptation requires gradual withdrawal, and abrupt cessation was used in every trial that included a washout without adverse consequence.

  • Cycling: No evidence supports cycling. Tolerance to the membrane effect has not been described, and DGLA enrichment is stable on continuous dosing, so scheduled breaks would simply lose the effect.

  • Stopping before procedures: The one mandatory interruption is 10–14 days before any procedure with bleeding risk. Dosing resumes at the previous level once clotting is confirmed; re-loading takes about three weeks.

Sourcing and Quality

  • Borage oil: Borago officinalis seed oil, the richest common source at 20–26% GLA, so about 240 mg per 1,000 mg capsule. Certified pyrrolizidine-alkaloid-free material matters here, since the plant produces liver-toxic alkaloids. Nordic Naturals and NOW market tested borage oils.

  • Evening primrose oil: Oenothera biennis seed oil, 7–10% GLA, about 80–100 mg per 1,000 mg capsule. The most-studied source and alkaloid-free, but reaching disease-level doses needs an impractical number of capsules.

  • Black currant seed oil: Ribes nigrum seed oil, 15–20% GLA, and the only common source that also supplies alpha-linolenic acid, an omega-3. Least studied of the three in clinical trials.

  • GLA-enriched safflower oil: A genetically modified Carthamus tinctorius oil concentrated to roughly 40% GLA, used in the 302-participant weight-maintenance trial. It delivers the highest GLA per capsule of any current source.

  • Third-party testing: The markers are a certificate of analysis stating measured GLA content, a peroxide value under about 5 milliequivalents per kilogram, and NSF, USP or Informed Choice certification. Independent testing has repeatedly found seed-oil products spoiled or underfilled.

  • Formulation and storage: Nitrogen-flushed softgels in opaque bottles with a distant expiry date, refrigerated after opening, hold up best. Polyunsaturated oils oxidise readily, and a rancid capsule delivers oxidised lipids rather than intact GLA.

Practical Considerations

  • Time to effect: Membrane loading takes about three weeks, but clinical change lags well behind. Rheumatoid arthritis trials needed six months, neuropathy trials six to twelve, and the skin-barrier study two months. Judging response before eight weeks is premature.

  • Common pitfall — capsule milligrams are not GLA milligrams: A 1,000 mg evening primrose capsule supplies roughly 90 mg of GLA. Protocols quoting 1.4–2.8 g/day of GLA therefore require 15–30 such capsules, which is why many self-directed attempts are silently underdosed.

  • Common pitfall — taking GLA without omega-3: Unopposed GLA raises circulating arachidonic acid. Adding EPA prevents this without blunting the rise in DGLA, and costs little relative to the GLA itself.

  • Common pitfall — stopping too early: Gastrointestinal complaints peak in the first two weeks and settle. Abandoning the protocol then, rather than dividing the dose and taking it with food, accounts for most self-reported failures.

  • Regulatory status: In the United States GLA is an unregulated dietary supplement with no approved indication. The United Kingdom licensed two evening primrose oil medicines in 1988 and withdrew both licences in October 2002 for insufficient efficacy evidence.

  • Cost and accessibility: Widely available and inexpensive at supplement doses. Disease-level doses are the exception: 2.8 g/day of GLA means a large daily capsule burden and a cost several times that of most single-nutrient supplements.

Interaction with Foundational Habits

  • Sleep: No direct interaction. GLA has no sedative or stimulant action and no trial has measured sleep. The indirect route is symptomatic: in arthritis and eczema populations, reduced joint pain or nocturnal itch should improve sleep continuity. No timing constraint applies, so dosing follows the largest meal regardless of bedtime.

  • Nutrition: Strongly interacting both ways. Absorption requires dietary fat, so capsules taken with a fat-containing meal load membranes faster. Zinc and magnesium are cofactors for delta-6 desaturase, and deficiency limits the body’s own GLA production. Heavy alcohol and refined sugar suppress the same enzyme, strengthening the case for supplying GLA directly.

  • Exercise: No direct interaction, and no blunting of training adaptation has been described — unlike high-dose antioxidants. The plausible indirect route is potentiating: prostaglandin E1 widens blood vessels, which would raise muscle perfusion, but no trial has tested GLA against any measure of exercise performance. No timing relative to training is established.

  • Stress management: Indirect only. GLA has no measured effect on cortisol or the stress axis. The connection runs the other way: chronic stress and the eating patterns that accompany it raise refined-carbohydrate and alcohol intake, both of which suppress delta-6 desaturase and so lower the body’s own GLA production.

Monitoring Protocol & Defining Success

Before starting, a plasma or red-cell fatty-acid panel establishes the starting position: GLA, DGLA, arachidonic acid and the Omega-3 Index together show whether there is room to move and whether omega-3 status is adequate to restrain onward conversion. A high-sensitivity C-reactive protein and a fasting lipid panel anchor the inflammatory and metabolic endpoints, and a liver enzyme panel gives a reference point for anyone using borage-derived products. Anyone on warfarin needs a documented baseline clotting time.

Ongoing testing follows the membrane timescale rather than the dosing schedule. The fatty-acid panel and inflammatory marker are repeated at 3 months, again at 6 months, then every 6–12 months on a stable dose. Clotting time is the exception, repeated at 1–2 weeks after starting and after every dose change.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Omega-3 Index 8–12% Shows whether the omega-3 counterweight to GLA is in place Percentage of EPA plus DHA in red-cell membranes. No fast needed; dried blood spot is adequate. Retest no sooner than 3 months, the red-cell turnover interval
Arachidonic acid to EPA ratio 3:1 to 8:1 Direct readout of whether GLA is stopping at DGLA or running on to arachidonic acid Conventional laboratories publish no reference range; the band shown is functional-practitioner guidance. Runs on the same panel as the Omega-3 Index
Dihomo-gamma-linolenic acid (DGLA) No established target; track the rise from the individual’s own pre-supplement value, typically a doubling at 1–2 g/day Confirms the supplement is absorbed and elongated as intended Reported as a percentage of plasma phospholipid fatty acids. Requires a full fatty-acid panel, not a standard lipid profile
High-sensitivity C-reactive protein Below 1.0 mg/L Tracks the inflammatory endpoint GLA is taken to move Conventional laboratories flag only above 3.0 mg/L. Fasting preferred; defer for 2 weeks after any infection or injury, which transiently raises it
Triglycerides Below 80 mg/dL (0.9 mmol/L) The blood fat most responsive to GLA in pooled trial data Conventional cut-off is below 150 mg/dL, far looser. Requires a 12-hour fast; best paired with HDL cholesterol on the same draw
International normalised ratio (INR) 2.0–3.0, or the range set for the specific indication Detects the additive anticoagulant effect before bleeding occurs Relevant only on vitamin K antagonists. Repeated 1–2 weeks after starting GLA and after each dose change
Alanine aminotransferase 10–26 U/L in women, 10–33 U/L in men Screens for liver injury from pyrrolizidine alkaloid exposure in borage products Abbreviated ALT; a liver enzyme released when liver cells are damaged. Conventional upper limits run to about 40 U/L, well above the functional range. Morning draw; avoid after strenuous exercise, which raises it

Qualitative markers worth tracking alongside the laboratory values:

  • Joint stiffness on waking, timed in minutes, and the number of tender joints
  • Burning, tingling or numbness in the feet, scored daily on a simple 0–10 scale
  • Skin dryness, visible scaling and itch intensity, particularly overnight
  • Ocular grittiness, burning and the frequency of artificial tear use
  • Ease of bruising, gum bleeding on brushing, and nosebleed frequency
  • Nausea, bloating or stool looseness in the first two weeks of any dose increase

Emerging Research

  • Weight-regain prevention trial reports pending: The GLASS trial randomised 302 adults who had lost at least 7% of body weight to 840 mg/day of GLA-safflower oil or placebo for 24 months, with neuropathy symptoms as a secondary endpoint. It completed in September 2023; no results have been posted.

  • GLA plus omega-3 in breast cancer survivors: A three-arm Serbian trial is recruiting 90 post-menopausal women on aromatase inhibitors (drugs that block oestrogen production after breast cancer) to receive evening primrose oil with fish oil, an anti-inflammatory diet, or placebo for four months, with FADS genotype among the analysed variables. Estimated completion November 2026.

  • Downstream compound fails in eczema: A Phase 2 trial of oral DGLA at 2 g/day in 219 adults with moderate-to-severe atopic dermatitis was terminated on interim analysis. This weakens the case, since it tested the active metabolite directly rather than the precursor.

  • Genotype-guided supplementation: Koletzko et al., 2019 set out how FADS1 and FADS2 variants determine who converts omega-6 fats efficiently. Whether pre-selecting low converters rescues the negative trials is the most testable open question and has not yet been attempted.

  • Circulating omega-6 fats and mortality: Wu et al., 2014 followed 2,792 adults aged 65 and over for 18 years and found GLA, DGLA and arachidonic acid levels unrelated to death from any cause. This weakens the longevity rationale built on shifting those fractions.

Conclusion

GLA is a plant seed-oil fat that the body turns into a second fat, and it is that second fat, not GLA itself, which feeds the calming signals. Everything about the compound follows from that one conversion and from a competing enzyme that can carry the same material into the inflammation-driving pathway instead.

The result is an unusually split record. Two uses hold up in repeated controlled trials: easing the nerve pain of long-standing diabetes, and reducing joint pain and tenderness in the autoimmune form of arthritis, both at doses well above what supplement labels supply. Effects on tear film, bone strength, acne and cold-triggered finger attacks rest on single small trials and stay unsettled. The two uses that once carried licensed medicines — eczema and cyclical breast pain — did not survive larger, independently funded testing. The safety record is mild — digestive upset is the usual complaint — though the fat slightly slows blood clotting, and without a fish-oil partner it feeds the inflammation-driving branch.

The evidence base carries a visible commercial shape. The company that built the original products funded most of the early positive work, several prominent reviews come from authors employed by or selling GLA oils, and the null results arrived mainly from independent groups. For health- and longevity-minded adults the most relevant finding is also the most deflating: blood levels of this fat family show no relationship to how long older adults live, so the longevity case rests on mechanism rather than outcomes.

Top - Benefits - Risks - Protocol